Dear Sir/Madam

Necrobiosis lipoidica (NL) is a burdensome degenerative disorder of collagen that usually affects the legs in those with diabetes mellitus, the prevalence within this population being approximately 0.3–1.2%. It is an inflammatory condition that, if untreated, inevitably results in scarring, and it can have a very negative impact on quality of life. It is not only demoralising by virtue of its unsightly appearance, but also very uncomfortable if it ulcerates, as well as being potentially dangerous given the albeit small risk of squamous cell carcinoma developing within long-standing lesions.

Numerous therapeutic options for NL have been advocated, including intra-lesional steroid, but there is a paucity of randomised controlled trial data regarding their efficacy. We report a case that acted as her own control in demonstrating the effectiveness of intra-lesional steroid injections.

A 19-year-old woman with poorly controlled type 1 diabetes mellitus, diagnosed five years previously and treated with a combination of rapid and long-acting insulins, presented with the recent onset of a non-ulcerated inflamed plaque proximal to her left medial malleolus. Histological examination of an incisional biopsy confirmed the clinical suspicion of NL, with large foci of necrobiotic granulomas and focal fibrosis within the dermis, surrounded by a chronic inflammatory cell infiltrate.

The lesion was treated with intra-lesional triamcinolone acetonide (10 mg/mL) in a piece-meal fashion as the patient disliked injections. The upper anterior quadrant was treated first, followed at two-monthly intervals by the lower quadrant. The lesion improved rapidly, and at four years post treatment, the long-term cosmetic result is excellent (Figure 1).

Figure 1. A plaque of necrobiosis lipoidica overlying the left lateral malleolus at a) baseline b) two months post infiltration of triamcinolone to right upper quadrant c) two months post infiltration to right lower quadrant and d) at four years post treatment indicating excellent long term cosmetic result.

We welcome correspondence and research letters to the journal. Research letters should be no more than 800 words with a maximum of 10 references, one table and/or one figure. These will usually be short reports of interim work or final reports of research that do not warrant a full research paper publication. Letters to the editor relating to any articles published in the Journal - Letters should ideally be submitted within 2 months following publication of the article on which the authors wish to comment, and should be no more than 600 words with up to 5 references.
anterior quadrant and then the posterior half. The benefit of the individual injections was clearly visible (see Figure 1). After six months a small recurrence was noted which was re-treated, and one year later there was no evidence of residual NL. There was initially a minimal loss of tissue substance and a mild sensation of numbness over the treated area, but overall the cosmetic result was excellent and the patient was discharged with photoprotection advice. Serendipitously, she was seen four years later when she attended as a relative, and there had been no recurrence and no clinically apparent scarring.

This case illustrates that intra-lesional triamcinolone is effective in the treatment of early NL and that the improvement is sustained. We recommend intra-lesional steroid as a well tolerated, easily administered treatment for NL, and suggest that early intervention has the potential to completely obviate the sequelae consequent on scarring.

**Conflict of interest** None

**Funding** None

**Disclaimer** No ethical approval required/applicable.

**Editor’s note** Necrobiosis is largely a clinical diagnosis and biopsy should be used with caution because of the possibility of ulceration. Perhaps the authors should consider comparing a topically applied strong steroid under occlusion with intralesional administration.

**References**


**Correspondence:** Stephanie L Ball
Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh EH3 9HA, UK
E-mail: stephanie.ball@nhslothian.scot.nhs.uk

https://doi.org/10.15277/bjd.2018.185

*Br J Diabetes* 2018;18:122-123